Macromolecular Crystallography Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, 166 10 Prague, Czech Republic.
Acta Crystallogr D Struct Biol. 2019 Jan 1;75(Pt 1):56-69. doi: 10.1107/S2059798318016492. Epub 2019 Jan 7.
Structures of a recombinant Kunitz-type serine protease inhibitor from Bauhinia bauhinioides (BbKI) complexed with bovine trypsin were determined in two crystal forms. The crystal structure with the L55R mutant of BbKI was determined in space group P6 at 1.94 Å resolution and that with native BbKI in the monoclinic space group P2 at 3.95 Å resolution. The asymmetric unit of the latter crystals contained 44 independent complexes, thus representing one of the largest numbers of independent objects deposited in the Protein Data Bank. Additionally, the structure of the complex with native BbKI was determined at 2.0 Å resolution from P6 crystals isomorphous to those of the mutant. Since BbKI has previously been found to be a potent inhibitor of the trypsin-like plasma kallikrein, it was also tested against several tissue kallikreins. It was found that BbKI is a potent inhibitor of human tissue kallikrein 4 (KLK4) and the chymotrypsin-like human tissue kallikrein 7 (KLK7). Structures of BbKI complexed with the catalytic domain of human plasma kallikrein were modeled, as well as those with KLK4 and KLK7, and the structures were analyzed in order to identify the interactions that are responsible for inhibitory potency.
从羊蹄甲属植物(BbKI)与牛胰蛋白酶复合物中确定了两种晶体形式的重组 Kunitz 型丝氨酸蛋白酶抑制剂的结构。L55R 突变体 BbKI 的晶体结构在 P6 空间群中以 1.94 Å 的分辨率确定,而天然 BbKI 的晶体结构在单斜空间群 P2 中以 3.95 Å 的分辨率确定。后者晶体的不对称单元包含 44 个独立的复合物,因此代表了蛋白质数据库中存储的最大数量的独立对象之一。此外,还从与突变体同晶的 P6 晶体确定了与天然 BbKI 复合物的结构,分辨率为 2.0 Å。由于 BbKI 先前被发现是胰蛋白酶样血浆激肽释放酶的有效抑制剂,因此还对几种组织激肽释放酶进行了测试。发现 BbKI 是人类组织激肽释放酶 4(KLK4)和胰凝乳蛋白酶样人类组织激肽释放酶 7(KLK7)的有效抑制剂。模拟了 BbKI 与人类血浆激肽释放酶催化结构域、KLK4 和 KLK7 的复合物结构,并对其进行了分析,以确定负责抑制效力的相互作用。